Modulation of Therapeutic Response
Modulation of Therapeutic Response
批准号:
9154244
负责人:
James Mitchell
金额:
$67.78万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AnimalsAttentionCDK4 geneCancer Cell GrowthCell AgingCell LineClinicalClinical TrialsDNA RepairDoseFibrosisFunctional ImagingGlutamineGoalsHead and Neck Squamous Cell CarcinomaHeat-Shock Proteins 90HumanHypoxiaIn VitroIonizing radiationLactate DehydrogenaseLungMalignant Epithelial CellMetabolicMetabolismModificationMolecularNormal tissue morphologyPharmaceutical PreparationsPhysiologyProcessProductionPublishingRadiationRadiation Induced DNA DamageRadiation OncologyRadiation therapyRadiation-Protective AgentsRadiation-Sensitizing AgentsRadiosensitizationResearchResearch DesignSirolimusStem cellsTestingTherapeuticToxic effectTranslatingWorkXenograft procedurecancer therapychemotherapyimaging platformimprovedin vivoinhibitor/antagonistinterestmTOR Inhibitornovelpre-clinicalpre-clinical researchpreclinical studypreventradiation effectradiation responseradioresistantrepairedresponsetreatment responsetumortumor microenvironment
中文摘要
为了改善癌症治疗,相当多的注意力已经放在辐射损伤的修饰上。正在研究各种化疗和/或分子靶向药物与放射的相互作用,以确定是否可以使肿瘤对放射治疗更敏感或使正常组织对放射治疗更耐受。中心目标是确定将导致净治疗收益的方法,从而改善癌症的放射治疗。该项目的一个目标是定义和更好地了解肿瘤生理学的这些方面,包括细胞和分子过程以及肿瘤微环境对治疗反应的影响。增强肿瘤对辐射的响应而不增强给定治疗区域内的正常组织的能力是期望的。我们已经完成并发表了一项研究,评估PI 3 K/mTOR抑制剂在人头颈癌细胞系中的作用。在体外和体内观察到抑制剂的令人印象深刻的放射增敏作用。在体内未观察到该组合的毒性。发现该抑制剂的作用机制是抑制辐射诱导的DNA损伤修复。该临床前研究的结果将提供必要的信息,以考虑将该药剂作为辐射增敏剂进行临床人体试验。我们已经证明,一种新的热休克蛋白90抑制剂是一种辐射增敏剂(在体外和体内)。已观察到该药物的显著体外辐射剂量调整因素,异种移植研究正在进行中。这种药物也有可能被转化为人体临床试验。我们已经启动了初步的体外研究,评估CDK 4/6抑制剂,这表明显着的放射增敏。我们继续评估一些代谢抑制剂作为辐射改性剂的工作假设下,抑制代谢(例如,减少ATP的生产)将减少辐射诱导的DNA损伤的修复。我们目前正在评估一种新的乳酸脱氢酶抑制剂与和不与谷氨酰胺抑制剂作为潜在的辐射调节剂的癌细胞生长。关于正常组织对辐射的反应,我们完成了一项研究,证明在动物食物中提供的雷帕霉素部分地通过防止辐射诱导的干细胞衰老来防止辐射诱导的肺纤维化。我们继续开发一种测试新型功能成像平台,以更好地了解肿瘤缺氧和代谢对荷瘤动物中辐射和药物诱导的肿瘤反应的贡献。总体而言,我们已经确定了许多临床前方法,以启动人类放射肿瘤学临床试验,以调节对肿瘤和正常组织的辐射效应。
英文摘要
In the interest of improving cancer treatment, considerable attention has been placed on the modification of radiation damage. The interaction of a variety of chemotherapy and/or molecularly targeted agents with radiation is under study to determine if tumors can be made more sensitive or normal tissues more resistant to radiation treatment. The central aim is to identify approaches that will result in a net therapeutic gain, thus improving cancer treatment with radiation. One goal of the project is to define and better understand those aspects of tumor physiology, including cellular and molecular processes and the influence of the tumor microenvironment on treatment response. The ability to enhance the response of the tumor to radiation, without enhancing normal tissue within a given treatment field is desirable. We have completed and published a study evaluating a PI3K/mTOR inhibitor in human head/neck carcinoma cells lines. Impressive radiosensitization by the inhibitor is observed in vitro and in vivo. No toxicity of the combination was observed in vivo. The mechanism of action of the inhibitor was found to be inhibition of radiation-induced DNA damage repair. The results of this pre-clinical study will provide the necessary information to consider a clinical human trial with this agent as a radiation sensitizer. We have demonstrated that a novel HSP90 inhibitor is a radiation sensitizer (in vitro and in vivo). Significant in vitro radiation dose modification factors have been observed with this agent and xenograft studies are ongoing. This agent also has potential of being translated into human clinical trials. We have initiated preliminary in vitro studies evaluating a CDK4/6 inhibitor, which demonstrates significant radiosensitization. We continue to evaluate a number of metabolic inhibitors as radiation modifiers under the working hypothesis that inhibition of metabolism (for example, decreased ATP production) will diminish the repair of radiation-induced DNA damage. We are currently evaluating a novel lactate dehydrogenase inhibitor with and without a glutamine inhibitor as potential radiation modifiers of cancer cell growth. With respect to normal tissue response to radiation, we completed a study demonstrating that rapamycin supplied in the animal's chow protects against radiation-induced lung fibrosis in part by preventing radiation induced stem cell senescence. We continue to develop an test novel functional imaging platforms to better understand the contribution of tumor hypoxia and metabolism on radiation and drug induced tumor response in tumor-bearing animals. Collectively we have identified a number of pre-clinical approaches to initiate human radiation oncology clinical trials for modulation of radiation effects on tumors and normal tissues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nitroxides as Protectors Against Oxidative Stress
-
批准号:10487178
-
项目类别:
-
资助金额:$23.68万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:8554011
-
项目类别:
-
资助金额:$66.27万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:8349242
-
项目类别:
-
资助金额:$32.13万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Redox Imaging using Nitroxides and MRI
-
批准号:8349161
-
项目类别:
-
资助金额:$55.7万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:8350044
-
项目类别:
-
资助金额:$70.69万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:10702438
-
项目类别:
-
资助金额:$114.64万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:8938387
-
项目类别:
-
资助金额:$63.42万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10262691
-
项目类别:
-
资助金额:$138.88万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:10262693
-
项目类别:
-
资助金额:$27.78万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:8158259
-
项目类别:
-
资助金额:$64.92万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:9153721
-
项目类别:
-
资助金额:$65.79万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Protection against Radiation-Induced Carcinogenesis
-
批准号:8937900
-
项目类别:
-
资助金额:$63.42万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:10926566
-
项目类别:
-
资助金额:$58.43万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10487176
-
项目类别:
-
资助金额:$118.41万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Imaging Probe Development Center
-
批准号:8746870
-
项目类别:
-
资助金额:$370.3万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Redox Imaging using Nitroxides and MRI
-
批准号:8552827
-
项目类别:
-
资助金额:$30.12万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Redox Imaging using Nitroxides and MRI
-
批准号:7592935
-
项目类别:
-
资助金额:$31.76万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10702987
-
项目类别:
-
资助金额:$143.3万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Modulation of Therapeutic Response
-
批准号:10926564
-
项目类别:
-
资助金额:$175.3万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:8763677
-
项目类别:
-
资助金额:$54.34万
-
财政年份:--
-
负责人:James Mitchell
-
依托单位:
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈立达
-
依托单位:
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:82202156
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位: